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Synopsis
Tumour formation is dependent on nutrient and oxygen supply from adjacent blood vessels. Angiogenesis inhibitors
can play a vital role in controlling blood vessel formation and consequently tumour progression by inhibiting endothelial
cell proliferation, sprouting and migration. The primary aim of the present study was to design cyclic thrombospondin-
1 (TSP-1) mimetics using disulfide-rich frameworks for anti-angiogenesis therapies and to determine whether these
peptides have better potency than the linear parent peptide. A short anti-angiogenic heptapeptide fragment from TSP-
1 (GVITRIR) was incorporated into two cyclic disulfide-rich frameworks, namely MCoTI-II (Momordica cochinchinensis
trypsin inhibitor-II) and SFTI-1 (sunflower trypsin inhibitor-1). The cyclic peptides were chemically synthesized and
folded in oxidation buffers, before being tested in a series of in vitro evaluations. Incorporation of the bioactive
heptapeptide fragment into the cyclic frameworks resulted in peptides that inhibited microvascular endothelial cell
migration, and had no toxicity against normal primary human endothelial cells or cancer cells. Importantly, all of the
designed cyclic TSP-1 mimetics were far more stable than the linear heptapeptide in human serum. The present study
has demonstrated a novel approach to stabilize the active region of TSP-1. The anti-angiogenic activity of the native
TSP-1 active fragment was maintained in the new TSP-1 mimetics and the results provide a new chemical approach
for the design of TSP-1 mimetics.
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INTRODUCTION
Tumour formation is dependent on nutrient and oxygen supply
from adjacent blood vessels [1]. An increase in new blood ves-
sel formation during tumour angiogenesis will enhance tumour
growth and provide an opportunity for cancer cells to metastasize
[2]. In the event of tumour angiogenesis, a range of angiogenic
growth factors is induced, including vascular endothelial growth
factor (VEGF) [3], platelet-derived growth factor (PDGF) and
basic fibroblast growth factor (bFGF) [4]. These angiogenic
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growth factors can increase proliferation, sprouting and mi-
gration in endothelial cells [5]. Endogenous angiogenesis in-
hibitors therefore play an important role in regulating tumour
formation [6].
Thrombospondin-1 (TSP-1) [7], a naturally occurring an-
giogenesis inhibitor, has been studied extensively due to its
potent anti-angiogenic activity observed in a range of in vitro
and in vivo experiments [8]. This 450-kDa protein with mul-
tiple domains [9] has a broad range of functions, including mod-
ulation of platelet aggregation, inflammation and angiogenesis
[10,11]. Only specific regions of TSP-1 contain sequences that
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inhibit angiogenesis, including a seven residue fragment (GVIT-
RIR) encompassing residues 454–460 of the human TSP-1 pro-
tein (Figure 1A), which has been shown to inhibit migration of
endothelial cells via interaction with CD36 [12–14]. CD36
is a scavenger receptor located on the cell surface and ex-
pressed in a broad range of mammalian cells (normal and
disease tissues) including microvascular endothelial cells, pha-
gocytes, adipocytes and hematopoietic cells [15]. Given its
diverse expression pattern on different cell types, it has been
associated with multiple biological functions via mediating cell-
specific responses [16,17]. Among all biological functions ex-
hibited by CD36, the CD36-TSP-1 interaction is known to
be an important process that acts as a negative regulator of
angiogenesis [17].
Various chemical approaches, including truncations of the ori-
ginal anti-angiogenic region of TSP-1 and unnatural amino acid
modifications, have been employed to modify the active hep-
tapeptide fragment to achieve better inhibition of angiogenesis
[13,14]. An example of a synthetic peptide derived from TSP-1
is the nonapeptide ABT-510, which reached phase II clinical tri-
als for the treatment of metastatic melanoma but these trials were
terminated due to a lack of clinical efficacy [18]. It has been
suggested that a higher dosage or combination with other cyto-
toxic drugs could improve the probability of ABT-510 becoming
a successful drug [18]. However, such approaches could increase
the risk of toxicity or adverse side effects and are likely to be
more costly to patients.
Another approach, designed to overcome these potential risks,
involves grafting the active heptapeptide into cyclic disulfide-
rich peptides [19], which are reported to have enhanced stabil-
ity over linear peptides [20]. In general, peptides have a range
of advantages over small-molecule drugs, including lower tox-
icity, high potency, selectivity and an ability to target a broad
range of diseases [21]. The naturally occurring cyclic disulfide-
rich peptides used in the present study are a 34-residue Mom-
ordica cochinchinensis trypsin inhibitor-II (MCoTI-II) [22] and
a 14-residue sunflower trypsin inhibitor-1 (SFTI-1) [23] (Fig-
ure 1B). Although these frameworks naturally have trypsin in-
hibitory activity, this activity can be abolished by a point mutation
of the active site residue [24]. Both frameworks have exceptional
stability, are non-toxic, and have the ability to resist thermal or
enzymatic degradation. The stability of these frameworks is due
to the cyclic cystine knot (CCK) motif of MCoTI-II [19,25],
and the extensive hydrogen bonding network of SFTI-1 [26].
Cyclic disulfide-rich peptides can be readily re-engineered due
to the availability of multiple loops within their frameworks,
with the possibility to incorporate a foreign active sequence
into these loops for delivery to a specific receptor. This ap-
proach has been used successfully in more than a dozen stud-
ies that yielded peptides with good potency towards targets of
interest [27–32].
The present study examines the prospect of grafting the hep-
tapeptide TSP-1 fragment into specific loops of MCoTI-II and
SFTI-1 to design a new suite of cyclic TSP-1 mimetics with the
ability to inhibit endothelial cell migration. The anti-angiogenic
heptapeptide from TSP-1 was chosen based on its ability to in-
Figure 1 Structure of human thrombospondin (TSP-1) and a
schematic representation of the approach used for the design
of cyclic TSP-1 mimetics
(A) The crystal structure of the human thrombospondin (TSP-1) type 1
repeat domains 2 and 3 was obtained from the protein data bank
(www.pdb.org; PDB ID: 3R6B). The ribbon diagram of the structure was
displayed using the MolMol program [61] and the human TSP-1 se-
quence was obtained from Uniprot (Accession No. P07996). The human
TSP-1 region corresponding to residues 454–460 (GVITRIR), highlighted
using dashed lines, was previously shown to confer broad-spectrum an-
ti-angiogenic activity and therefore was selected for the present study
[9]. (B) This active region (marked by black amino acid residues) was in-
corporated into two cyclic disulfide-rich frameworks, i.e., SFTI-1 (PDB ID:
1JBL) and MCoTI-II (PDB ID: 1HA9) (three-dimensional structures shown
inside circular amino acid sequence). The disulfide bond connectivity is
illustrated schematically (upper half of panel), with cysteines labelled
using Roman numerals. The first isoleucine of the heptapeptide was
modified to a D-Ile, as previous studies suggested its bioactivity could
be enhanced. Different loops of the cyclic framework are represented
as ‘L1, L2 etc.’
hibit migration of endothelial cells, and the goal was to use
cyclization to improve the potency and stability of the TSP-
1 fragment without introducing toxicity. The rationale for the
present study is illustrated in Figure 1(B). The newly designed
cyclic TSP-1 mimetics were chemically synthesized using native
chemical ligation [33] and were screened in a range of in vitro
assays. Grafting an active TSP-1 fragment into cyclic disulfide-
rich frameworks is a novel approach for the TSP-1 research area
and in the current study we have produced promising peptide-
based inhibitors for targeting a range of blood vessel overgrowth
diseases such as tumour angiogenesis, atherosclerosis and retinal
disease.
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EXPERIMENTAL
Peptide synthesis
The heptapeptide TSP-1 (GViTRIR), where ‘i’ is D-
isoleucine, was grafted into two cyclic disulfide-rich frameworks
(MCoTI-II and SFTI-1) to form MCo-TSP-1 and SFTI-TSP-
1. Both grafted peptides were synthesized using manual
solid-phase peptide synthesis on a CS Bio synthesizer us-
ing Boc chemistry. In this method, Boc-Gly-PAM resin was
used along with S-tritylmercaptopropionic acid as a linker,
and using N,N,N′,N′-tetramethyl-O-(6-chloro-1H-benzotriazol-
1-yl)uronium hexafluorophosphate (HCTU) for amino acid ac-
tivation. The linear heptapeptide was synthesized on a Sym-
phony microwave synthesizer using chlorotritylchloride resin
and with Fmoc chemistry using piperidine for amino acid ac-
tivation. The linear heptapeptide was constructed with normal N-
and C-termini without chemical modifications. The peptides were
synthesized on a 0.5 mmol scale. Peptides made using Boc chem-
istry were cleaved from the resin using hydrogen fluoride with
p-cresol as a scavenger at 0 to 5 ◦C for 1 h. Fmoc-synthesized pep-
tides were cleaved using a mixture of 95 % (v/v) trifluoroacetic
acid/2.5 % (v/v) triisopropylsilane/2.5 % (v/v) H2O. Traces of
trifluoroacetic acid were removed using a rotary evaporator, and
the remaining peptide in solution was precipitated with diethyl
ether and extracted in 50 % (v/v) acetonitrile/50 % (v/v) H2O.
The aqueous layer was lyophilized and the resulting crude pep-
tides were purified using Shimadzu reverse-phase HPLC. Nat-
ive SFTI-1 was synthesized using Boc chemistry and MCoTI-II
was isolated directly from M. cochinchinensis seed extract as
described by Chan et al. [34].
Peptide purification and folding conditions
Crude peptides obtained from either plant extracts or chem-
ical synthesis were purified using a series of Phenomenex
C18 columns on reverse-phase HPLC. Gradients of 1 %/min of
0–80 % solvent B (90 % (v/v) acetonitrile in 0.045 % (v/v) tri-
fluoroacetic acid in H2O) and solvent A (0.05 % (v/v) trifluoro-
acetic acid in H2O) were used and the eluent was monitored at
215 and 280 nm. The purity of the peptides was examined on a
Nexera ultra HPLC (Shimadzu) with a flow rate of 0.4 mL/min
on a 0.8 mL/min Agilent column using a 2 % gradient of 0–
50 % solvent B and masses were determined by electrospray
mass spectrometry. Only peptides with greater than 95 % purity
were used in assays. MCo-TSP-1 peptide was folded in one-
pot oxidation solution, which contained 0.1 M ammonium bicar-
bonate (pH 8.5) for 24 h. Both native SFTI-1 and SFTI-TSP-1
peptides were folded in a two-step oxidation condition, which
included cyclization of the peptide with 0.1 M ammonium bi-
carbonate (pH 8.0)/0.1 M TCEP for 24 h then oxidized in 0.1 M
ammonium bicarbonate (pH 8.0) for another 24 h. MCoTI-II did
not need to be oxidized, as it was isolated directly from the seed
extract.
Cell culture
HUVECs were cultured in EGM (endothelial cell growth
media)-2 BulletKit supplemented with SingleQuots (endothelial
basal media-2 (EBM-2) supplemented with growth factors, cy-
tokines, antibiotics; Lonza)/10 % (v/v) FBS). HMVECs were cul-
tured in EGM-MV BulletKit supplemented with SingleQuots
(EBM-2 supplemented with growth factors, cytokines, anti-
biotics; Lonza)/20 % (v/v) FBS. HT-29 (colon cancer cells)
and MCF-7 cells (breast cancer cells) were cultured in 10 %
(v/v) FBS/DMEM with 1 % (v/v) penicillin–streptomycin (5000
U/mL; Life Technologies). For PC3 cells (prostate cancer cells),
10 % (v/v) FBS/RPMI 1640 media with 1 % (v/v) penicillin–
streptomycin (5000 U/mL; Life Technologies) was used during
culture. All cells were maintained at 37 ◦C in 5 % CO2.
Cell cytotoxicity assay
All cells were maintained using the media conditions described
above, and passages 2–10 were used for all cell lines. 5 × 103
cells/well (100 μL) were used for both HUVECs and HMVECs,
and 2.5 × 103 cells/well (100 μL) were used for other cell lines
in this assay. All cells were allowed to attach for 24 h after plat-
ing. Cells were treated with fresh media the next day, before
the addition of peptides. After the addition of peptides (at a
range of final concentrations: 10 μL; 50 μM, 25 μM, 10 μM,
5 μM, 1 μM, 0.5 μM, 0.1 μM and 0.01 μM), cells were incub-
ated for 2 h. Except for HMVECs, the final peptide concentration
range tested was 10-fold dilutions from 10 μM to 0.00 001 μM
(10 μL) and these cells were incubated for 24 h. 0.1 % (v/v) Tri-
ton X-100 (10 μL) was used as a positive control. After the 2-h
incubation, 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium
bromide (MTT) (10 μL; 5 mg/mL in PBS) was added, and cells
were incubated for a further 4 h. Supernatant was then removed
and 100 μL DMSO added to solubilize formazan salts. Experi-
ments were performed in triplicate. Cell numbers were followed
at 600 nm.
Cell proliferation assay
All cells were maintained using the media conditions described
above, and passages 2–10 were used for all cell lines. Cell
numbers of 2.5 × 103 cells/well (100 μL) were used for both
HUVECs and HMVECs, and 1.5 × 103 cells/well (100 μL) were
used for other cell lines in this assay. All cells were allowed to at-
tach for 24 h after plating. Cells were treated with fresh media the
next day, before the addition of peptides and then incubated for
72 h. Similar peptide concentrations to those mentioned above
(in the cell cytotoxicity section) were used. 0.1 % (v/v) Triton
X-100 (10 μL) was used as a positive control. After 72 h of in-
cubation, MTT and DMSO were added and analysed using the
same method as described above.
Transwell migration assay using HUVECs
An endothelial cell migration assay was conducted to determ-
ine the anti-angiogenic activity of newly designed cyclic TSP-1
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mimetics. This assay was established based on previous studies
using a HUVEC migration assay [35–38]. A 24-well plate loaded
with 8 μm polycarbonate inserts (Corning) was used. Prior to the
assay, all inserts were pre-coated with attachment factor (Gibco)
for 30 min. Passages 6–10 were used for HUVECs, and were
maintained in the conditions described above. Prior to the start
of this assay, HUVECs were serum-starved overnight (16 h) and
washed with PBS. HUVECs were detached with non-enzymatic
cells dissociation buffer (Gibco) for 10 min, and resuspended in
0.1 % (v/v) FBS/EBM-2 and centrifuged at 347 g for 8 min. Pep-
tides in varying concentrations (0.001–50 μM) were added to the
cell suspension and incubated for 30 min at 37 ◦C before adding
into the insert. HUVECs with a cell number of 1 × 106 cells/well
(100 μL) were seeded to the apical well and 600 μL media sup-
plemented either with or without 0.3 nM VEGF was added to the
basolateral well. Cells with 0.1 % (v/v) FBS/EBM-2 basal me-
dia were used as negative controls, whereas cells with 0.3 nM of
VEGF were used as positive controls. Cells were allowed to mi-
grate for 4 h at 37 ◦C. After incubation, the cell suspension from
the top chamber was gently removed using a cotton swab and the
insert was fixed with 4 % (v/v) formaldehyde/PBS and stained
with 0.05 % (v/v) crystal violet/PBS. Next, cells were destained
with 10 % (v/v) acetic acid/H2O. For each insert, 100 μL of the
destained solution was transferred into a 96-well plate and ab-
sorbance was read using Power Wave XS (Biotek) spectrometer
at 590 nm. Experiments were done in triplicate.
Transwell migration assay using HMVECs
This assay was established in a similar manner as described
above; however, additional procedures specifically for HMVECs
were included based on previous studies [39–41]. HMVECs
within passages 7–12 were used and maintained as above. Prior
to the start of the assay, HMVECs were serum-starved overnight
(16 h) and washed with PBS. HMVECs were detached with
0.25 % (w/v) trypsin/EDTA solution (Gibco) for 2 min, and resus-
pended in 0.1 % (v/v) FBS/EBM-2 media only and centrifuged
at 347 g for 2 min. Peptides at various concentrations (0.00001–
10 μM) were added to the cell suspension and incubated for
30 min at 37 ◦C before adding into the insert. HMVECs with
a cell number of 0.5 × 106 cells/well (100 μL) were seeded to
the apical well and 600 μL of media supplemented with/without
1 nM VEGF/5 % FBS was added to the basolateral well. Cells
with 0.1 % (v/v) FBS/EBM-2 basal media was used as a negative
control, whereas cells with 1 nM of VEGF/5 % (v/v) FBS were
used as a positive control. Cells were allowed to migrate for 24 h
at 37 ◦C. After incubation, cells were treated as described above,
for the HUVEC migration assay.
Hemolytic assay
Human red blood cells were used to measure the hemolysis of all
peptides, with melittin used as a positive control. Peptides con-
centrations were 50 μM, 25 μM, 10 μM, 5 μM, 1 μM, 0.5 μM,
0.1 μM and 0.01 μM. Melittin was tested at eight concentrations,
with two-fold dilution from a concentration of 20 μM. Sample
absorbance was measured at 415 nM using a BioTek PowerWave
XS instrument, as described previously [29]. Experiments were
done in triplicate.
Stability assay
All peptides were tested on human serum from male AB plasma
(Sigma–Aldrich) at an initial concentration of 300 μM. Peptide
incubation time points were 0, 2, 4, 8, 16 and 24 h. Samples
were prepared according to previously described methods [29].
Briefly, 90 μL of supernatant was taken at each time point and
chromatographed on a 0.3 mL/min Phenomenex column using
a linear 1 %/min gradient of 0–50 % solvent B on an analytical
reverse-phase HPLC (Agilent). The elution times for all peptides
were determined by the serum control at 0 h. The stability of
each peptide for each time point was calculated as the height
of the serum-treated peptide peak at 215 nm as percentage of the
height of the 0-h serum-treated control. Experiments were done
in triplicate.
NMR analysis
Peptides were dissolved in 90 % (v/v) H2O/10 % (v/v) D2O at a
concentration of 1 mM at pH 5.5, using D2O at 99.9 % purity ob-
tained from Cambridge Isotope Laboratories, Woburn, MA. One-
dimensional (1H) and two-dimensional (TOCSY and NOESY)
spectra were recorded at 298 K on a Bruker Avance 600 MHz
spectrometer. Mixing times of 200–300 ms were employed for
NOESY experiments. Spectra were assigned using CCPNMR
[42].
Statistical analysis
All statistical analyses were done using GraphPad Prism version
6. All data represent average mean +− S.D. Statistical significance
were performed using one-way analysis of variance (ANOVA)
with Dunnett’s multiple comparison test was applied in the ana-
lysis. P 0.05 was considered statistical significant.
RESULTS
Design and synthesis approach of cyclic TSP-1
mimetics
The sequences of the synthetic peptides are given in Table 1.
The first isoleucine residue in the TSP-1 heptapeptide was mod-
ified to a D-amino acid due to the enhanced activity observed
with this modification in a previous study [13]. The heptapeptide
was incorporated into the secondary loop (loop 2) of SFTI-1 and
loop 6 of MCoTI-II. Native chemical ligation and Boc chem-
istry methods were employed to cyclize the N- and C-termini
of cyclic TSP-1 mimetics (MCo-TSP-1 and SFTI-TSP-1) [33],
which were then oxidized to form the native disulfide bonds.
Synthetic SFTI-1 was oxidized according to procedures outlined
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Table 1 Peptide sequences involved in the present study
*Cyclic peptide. †The lower-case ‘i’ represents D-isoleucine (D-Ile).
Molecular
Peptides Sequences mass (Da)
TSP-1 GViTRIR† 814.00
SFTI-1* CTKSIPPICFPDGR 1513.79
SFTI-TSP-1* CTKSIPPICGViTRIR† 1737.15
MCoTI-II* CPKILKKCRRDSDCPGACICRGNG-
YCGSGSDGGV
3452.94
MCo-TSP-1* CPKILKKCRRDSDCPGACICRGNG-
YCGViTRIR†
3632.33
in the methods section, whereas MCoTI-II was isolated directly
from a seed extract. Only peptides that were correctly folded, had
the correct mass and were greater than 95 % pure were used in
the in vitro tests (Supplementary Figure S1). All peptides were
readily soluble in water, which allowed them to be tested in a
range of cell-based assays.
NMR analysis of the re-engineered cyclic TSP-1
mimetics
It was important to analyse the structure of the newly designed
cyclic TSP-1 analogues to determine whether these peptides ad-
opt similar conformations to their native frameworks. In general,
the αH NMR chemical shifts of MCo-TSP-1 and SFTI-TSP-1
were found to be similar to MCoTI-II and SFTI-1, respectively,
which indicates that the native fold was maintained in the graf-
ted peptides (Figure 2). There were some differences in αH
NMR chemical shifts at the grafted regions, but this was ex-
pected due to the differences in amino acid residues in these
regions.
Endothelial cell migration on HUVECs and HMVECs
We tested the inhibitory activity of our newly designed cyclic
TSP-1 mimetics against both HMVECs and HUVECs, as previ-
ous studies reported that peptides derived from TSP-1 have the
ability to inhibit endothelial cell migration more potently in HM-
VECs [8,12] (a cell line that overexpresses CD36) than HUVECs
(a cell line that expresses integrins but not CD36) [35]. Based on
the low expression levels of CD36 in cancer cells (PC-3, MCF-7
and HT-29) showed by CD36 antibody staining (PC-3 and MCF-
7) from the Human Protein Atlas portal (www.proteinatlas.org)
[43] and CD36 RNA expression of HT-29 and MCF-7 from
the Expression Atlas (http://www.ebi.ac.uk/gxa) [44] databases,
these cell lines were not examined in the cell migration as-
say. The inhibitory activity of the peptides was compared with
VEGF, a potent growth factor that stimulates angiogenesis. We
found that the TSP-1 heptapeptide, SFTI-TSP-1 and MCo-TSP-1
could more effectively suppress the migration of HMVECs than
HUVECs (Figures 3A and 3B). Among the peptides tested
on HMVECs, MCo-TSP-1 was more effective at suppressing
migration compared with SFTI-TSP-1 and linear TSP-1 hep-
tapeptide (Figure 3B). At 10 μM, the linear TSP-1 heptapeptide,
SFTI-TSP-1 and MCo-TSP-1 displayed 20 %, 45 % and 30 %
higher inhibition of HMVECs, respectively, when compared
with the same concentration of these peptides incubated with
HUVECs. At 1 μM, SFTI-TSP-1 and MCo-TSP-1 displayed
29 % and 41 % higher inhibition of HMVEC migration, re-
spectively, compared with HUVECs at the same concentration.
Interestingly, MCo-TSP-1 still conferred approximately 20 %
inhibition on HMVEC migration at 100 nM. Both native frame-
works did not have an inhibitory effect either on HUVECs
(data not shown) or HMVECs (Figure 3C). Overall, the newly
designed cyclic TSP-1 mimetics had enhanced inhibition of
HUVEC or HMVEC migration compared with the linear TSP-1
heptapeptide.
Cell proliferation study on primary human
endothelial and cancer cells
Although the cyclic TSP-1 mimetics showed significant inhib-
ition in the endothelial cell migration assay, it was important
to confirm that this activity was not an artefact of cell toxicity.
Hence the toxicity of the peptides was screened against primary
human cells (HUVECs and HMVECs) and selected cancer cell
lines (HT-29, MCF-7 and PC-3). None of the peptides affected
cell viability during a 2-h incubation (results not shown), which
eliminates the possibility that peptide toxicity causes inhibition
of cell migration. To evaluate the effect of these peptides on
cells that were in a proliferative state, a longer incubation period
was also tested. When the peptides were incubated with cells
for up to 72 h, none of the peptides had an effect on HUVECs
but a minor decrease in cell viability was observed on HM-
VECs, HT-29, MCF-7 and PC-3 cells, with IC50 values of more
than 50 μM (Figures 4A and 4B), indicating that these peptides
did not confer a strong reduction on cell viability in these cell
lines.
Hemolytic activity and peptide stability
In addition to evaluating cytotoxicity and cell proliferation ef-
fects on human primary endothelial (non-cancerous) and cancer
cells, it was also of interest to assess the toxicity of the peptides
against human red blood cells. The peptides were tested in the
concentration range of 0.01–50 μM and the native peptides and
TSP-1 mimetics were non-haemolytic to human red blood cells
when compared with melittin, a highly haemolytic peptide from
honeybee venom (Figure 5A).
To assess the stability of the peptides, they were incubated in
human serum. Linear TSP-1 heptapeptide was degraded within
24 h, in contrast with the cyclic peptides, as shown in Figure 5(B).
The TSP-1 heptapeptide was degraded despite containing a D-
amino acid. Although MCo-TSP-1 has lower stability than SFTI-
TSP-1, more than 50 % of both peptides remained in human
serum over a 24-h period. Furthermore, both of these cyclic TSP-
1 mimetics have enhanced stability compared with their linear
counterparts.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0. 5
L.Y. Chan, D.J. Craik and N.L. Daly
Figure 2 NMR analysis of cyclic TSP-1 mimetics
(A) Comparison of SFTI-1 and SFTI-TSP-1 αH chemical shifts. (B) Comparison of MCoTI-II and MCo-TSP-1 αH chemical
shifts. All 1H NMR spectra were recorded at 298 K. The active TSP-1 fragment is highlighted in bold and the region for
comparing native and inserted sequence in different cyclic frameworks is in a grey box. Disulfide bond connectivity is
indicated with bold lines and each cysteine is labelled with Roman numerals.
DISCUSSION
Rational design of cyclic TSP-1 mimetics
The aim of the present study was to design cyclic
thrombospondin-1 (TSP-1) mimetics using disulfide-rich frame-
works and examine their effects on endothelial cell migration.
Both MCoTI-II and SFTI-1 frameworks were used: the SFTI-1
framework contains a single disulfide bond that effectively di-
vides the sequence into two backbone loops, termed the trypsin
inhibitory loop (loop 1) and the secondary loop (loop 2); by con-
trast, the MCoTI-II framework contains three disulfide bonds and
six loops. The linear heptapeptide (GViTRIR) was incorporated
into loop 2 of SFTI-1 and loop 6 of MCoTI-II, with these loops
chosen based on successful examples of the grafting of other
epitopes into these loops [29–32,45]. The peptides were readily
synthesized and folded and were highly soluble in water. Solubil-
ity is important, because a previous example of a TSP-1 derived
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Figure 3 Endothelial cell migration assays for HUVECs and HMVECs
(A) The percentage of HUVEC migration following treatment with TSP-1, SFTI-TSP-1 and MCo-TSP-1. (B) The percentage
of HMVEC migration following treatment with TSP-1, SFTI-TSP-1 and MCo-TSP-1. (C) The percentage of HMVEC migration
following treatment with native cyclic frameworks, SFTI-1 and MCoTI-II. All peptides were compared with VEGF (positive
control) with 100% HUVEC or HMVEC migration. Peptides were added in the presence of either 0.3 nM VEGF or 1 nM/5%
FBS VEGF (bottom chamber). The data represent mean +− S.D. (n = 3). Data were normalized to the mean VEGF control.
P-values are represented as follows: ****P0.0001, ***P0.001, **P0.01 and *P0.05.
peptide, ABT-526, led to challenges in pharmacokinetic studies
in animals due to poor solubility [14]. The excellent solubility of
the MCoTI-II and SFTI-1 frameworks favours their use in a wide
range of grafting applications.
Backbone cyclization approach improved stability
and non-toxic to cells
We utilized non-natural amino acid substitution [46] and back-
bone cyclization [47] chemical approaches to improve linear
TSP-1 fragment stability. Alternative approaches such as cap-
ping of the N- or C-termini [13] or N-methylation [48] have also
been used to optimize bioactive peptides in other studies. The
non-natural amino acid substitution strategy here involved repla-
cing the first isoleucine residue of linear TSP-1 with D-Ile, as
this modification is known to favour interaction with the CD36
receptor [13]. Another reason for this modification was the fact
that D-amino acids can assist in improving stability, an important
factor given that angiogenesis involves a vast range of proteolytic
enzymes [49,50]. Both MCoTI-II and SFTI-1 contain a cyclic
backbone that is amenable to incorporation of target epitopes,
and this structural feature reinforced the stability of the TSP-1
mimetics; both cyclic TSP-1 peptides were more stable in serum
over 24 h than the linear TSP-1 heptapeptide. SFTI-TSP-1 was
more stable than MCo-TSP-1, probably due to the more rigid
framework of SFTI-TSP-1. Importantly the NMR data showed
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Figure 4 Cell proliferation assay
All peptides were incubated for 72 h in five different cell lines, including the (A) primary human endothelial cells, (i) HUVECs
and (ii) HMVECs, and (B) cancer cells, (i) HT-29, (ii) MCF7 and (iii) PC-3. Each peptide was tested in triplicate and the data
represent mean +− S.D.
that the linear TSP-1 fragment adopts a similar conformation in
both frameworks. No toxic effects were observed for the peptides
against human primary endothelial cells, cancer cells or red blood
cells over a 2-h incubation period.
Effects of linear, cyclic TSP-1 peptides and their
native cyclic frameworks on cell proliferation study
Anti-proliferative activity was measured for all peptides over
a 72-h period. None of the peptides showed any activity on
HUVECs, probably due to the lack of CD36 expression in this cell
line compared with HMVECs; however, the peptides had minor
anti-proliferative effects on HT-29, MCF-7, PC-3 and HMVECs
at high concentrations. The native (i.e. un-grafted) MCoTI-II and
SFTI-1 native frameworks also had minor anti-proliferative ef-
fects on HT-29 [51] and PC-3, possibly due to the expression of
matriptase receptors (type-II transmembrane serine protease) on
these cells [52]. Although only a weak anti-proliferative effect
was observed, Gray et al. [53] recently reported that MCoTI-II in-
hibited invasive cell migration in a matriptase over-expressed PC-
3 cell line. It is possible that MCoTI-II has weak anti-proliferative
activity by controlling growth of PC-3 cells but exhibits a stronger
inhibitory effect on cell migration by controlling cell motility.
The mild anti-proliferative effect coupled with the lack of tox-
icity observed in these peptides gives them an advantage over
conventional cytotoxic drugs, which often have a narrow thera-
peutic index and high toxicity profile [54,55].
Grafting of linear TSP-1 fragment into MCoTI-II and
SFTI-1 affects endothelial cell migration
Figure 6 gives a schematic overview of the effects of the grafted
cyclic peptides on cell migration. The linear and cyclic TSP-1
mimetics and native frameworks were examined in a human en-
dothelial cell migration assay using two cell types, i.e., HUVECs
and HMVECs. TSP-1 derived peptides target HMVECs through
the CD36 receptor [12,56] and have an inhibitory effect on
HUVEC migration via targeting the β-integrin receptor instead
of CD36 [35]. We showed that cyclic TSP-1 mimetics have higher
potency towards HMVECs compared with HUVECs. This dif-
ference in potency is likely a result of the difference in expression
of CD36 receptors in HMVECs compared with large vessel cells
such as HUVECs. Previous studies using flow cytometric analysis
have shown the presence of CD36 on the surface of HMVECs,
in contrast with HUVECs where the antibodies failed to detect
the presence of CD36 [57,58]. This difference in potency is also
consistent with previous studies on thrombospondin-1 type-1 re-
peats (TSR) by Short et al. [35], who reported 35 % inhibition
could be achieved on HMVECs at 5 nM but 16 nM was required
for 60 % inhibition on HUVECs. The TSP-1 heptapeptide grafted
into the MCoTI-II framework resulted in better inhibition of cell
migration than the SFTI-1 framework grafts, possibly because
the larger framework provides better opportunity for the delivery
of the TSP-1 fragment to its receptor than SFTI-1 [59]. Addition-
ally, the site of the incorporation of the TSP-1 peptide in loop
6 of MCoTI-II offers greater flexibility compared with SFTI-1
as the SFTI-1 framework is small, with a β-hairpin constrained
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Figure 5 Evaluation of cyclic TSP-1 mimetics on human red blood
cells and human serum
(A) Hemolytic assays on peptides and frameworks, with melittin as a
positive control. (B) Stability in human serum, with the graph showing
the percentage of peptide remaining over a 24-h incubation. All data
are represented as mean +− S.D. (n = 3).
structure [26]. Although SFTI-TSP-1 was observed to be less po-
tent than MCo-TSP-1, both peptides showed better stability and
potency than their linear counterpart. On the other hand, the cell
penetration properties of cyclic frameworks could also play a role
in the different route of entry into cells, as D’Souza et al. [60]
have recently shown that MCoTI-II is more efficiently internal-
ized into cells than SFTI-1. This fits the results of cell migration
study, where MCo-TSP-1 has better potency than SFTI-TSP-1.
Although these peptides do not have as high potency as ABT-510
(inhibition of HMVEC migration: IC50 = 0.89 nM [14]), they are
still active at low micromolar (SFTI-TSP-1) or nanomolar (MCo-
TSP-1) concentrations. These data suggest TSP-1 mimetics act
against HMVECs via a CD36-dependent pathway.
Conclusions
Re-engineering linear TSP-1 fragment into cyclic frameworks
appears to be a promising approach for developing potential anti-
angiogenesis therapeutics. This approach resulted in improved
stability and enhanced inhibition of endothelial cell migration
without being toxic to human red blood cells, primary endothelial
Figure 6 A schematic overview of the results from the present
study
Newly designed cyclic TSP-1 analogues (SFTI-TSP-1 and MCo-TSP-1)
were able to suppress HMVEC migration. Interestingly, these peptides
had better inhibition of HMVEC migration (highlighted with a square box)
compared with HUVECs, probably due to the overexpression of CD36
receptors in HMVECs but not in HUVECs. It is also possible that these
peptides have the ability to inhibit VEGF as well since VEGF was ad-
ded during the migration assay. Weaker inhibition was also observed in
HUVEC migration although CD36 was not expressed in these cells. This
might be due to the possibility of TSP-1 being able to inhibit β1-integrin
receptors expressed in HUVECs. This was also observed in Short et
al. [35]. Overall, cyclic TSP-1 analogues have better stability and po-
tency (pathway shown in solid line) than the linear heptapeptide TSP-1
(pathway shown in dashed line).
or cancer cells. Many FDA-approved cancer drugs (i.e. antibod-
ies and small molecules) possess unwanted side effects, includ-
ing increased risk of heart disease. The low toxicity profile of the
cyclic TSP-1 peptides thus provides them a potential advantage
over current drugs. Furthermore, since there are limited peptide-
based drugs in the anti-angiogenesis field, the design and devel-
opment of new generation drug candidates based on naturally
occurring cyclic peptides provides an opportunity to better ex-
plore this therapeutic space. Although the cyclic TSP-1 peptides
did not confer potency equivalent to ABT-510, they are active
and exhibit excellent stability, thus demonstrating an opportun-
ity for SFTI-1 and MCoTI-II frameworks in developing the next
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generation of thrombospondin mimetics. Further studies of these
cyclic TSP-1 mimetics in animal tumour models will be import-
ant to evaluate the clinical relevance of these findings and to
determine the interaction of these peptides to their correspond-
ing receptors in in vivo settings. Overall, the present study has
resulted in promising angiogenesis inhibitors with potential for
therapy in cancer and other diseases caused by overgrowth of
blood vessels.
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